SCHEDULE: BioNTech Major Shareholder Ownership Update
Beneficial Ownership Report
ATHOS KG, AT Impf GmbH, and Thomas Maier maintain a 40.2% beneficial ownership stake in BioNTech SE.
Summary
- The filing is an Amendment No. 6 to Schedule 13G regarding beneficial ownership of BioNTech SE.
- Reporting persons ATHOS KG, AT Impf GmbH, and Thomas Maier collectively hold 101,702,378 ordinary shares.
- This stake represents 40.2% of the total outstanding ordinary shares of BioNTech SE.
- The ownership percentage is calculated based on 252,884,261 shares outstanding as of March 31, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral regulatory filing confirming existing ownership levels without indicating new strategic shifts or financial changes.
Positives
- Continued long-term commitment from major shareholders, the Strungmann family-linked entities.
- Stable ownership structure with no reported divestment.
Negatives
- High concentration of ownership (40.2%) by a single group may limit free float and influence voting outcomes.
Risks
- Concentrated ownership could lead to potential conflicts of interest or influence over corporate governance decisions.
Future Outlook
No specific forward-looking business guidance provided; the filing is a regulatory disclosure of ownership status.
Industry Context
StockSavvy.ai notes that large, stable block holdings by founding families or early investors are common in the biotechnology sector, often providing a buffer against short-term market volatility while signaling long-term confidence in the company's pipeline.
Comparison to Industry Standards
- The 40.2% ownership stake is consistent with the historical influence of the Strungmann family in BioNTech's capital structure.
- This level of concentration is typical for high-growth biotech firms where early venture backers retain significant control.
Related Party Transactions
- The reporting persons are linked to the families of Thomas and Andreas Strungmann, who are significant stakeholders.
Stakeholder Impact
- Provides transparency to shareholders regarding the concentration of voting power.
Next Steps
- Continued monitoring of future 13G/13D filings for any changes in the reporting persons' holdings.
Key Dates
| Date | Description |
|---|---|
| 2022-02-11 | Date of the original Joint Filing Agreement. |
| 2026-03-31 | Date of event requiring filing and reference date for outstanding shares. |
| 2026-05-05 | Date of Issuer's Form 6-K reporting outstanding shares. |
| 2026-05-14 | Date of signature and filing of the Schedule 13G amendment. |
Keywords
BioNTech, BNTX, Schedule 13G, Beneficial Ownership, ATHOS KG, Strungmann, Shareholder
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.